{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:34:11Z","timestamp":1776321251263,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00277-019-03695-x","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T19:02:38Z","timestamp":1556650958000},"page":"1583-1592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell\/beta-thalassemia and correlates with markers of hemolysis and bone mineral density"],"prefix":"10.1007","volume":"98","author":[{"given":"Ersi","family":"Voskaridou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Dimopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veroniki","family":"Komninaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Repa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"issue":"9","key":"3695_CR1","doi-asserted-by":"publisher","first-page":"a011692","DOI":"10.1101\/cshperspect.a011692","volume":"2","author":"TN Williams","year":"2012","unstructured":"Williams TN, Weatherall DJ (2012) World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med 2(9):a011692. \n                    https:\/\/doi.org\/10.1101\/cshperspect.a011692","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"3695_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ajh.24231","volume":"91","author":"D Rund","year":"2016","unstructured":"Rund D (2016) Thalassemia 2016: modern medicine battles an ancient disease. Am J Hematol 91(1):15\u201321. \n                    https:\/\/doi.org\/10.1002\/ajh.24231","journal-title":"Am J Hematol"},{"issue":"16","key":"3695_CR3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarre C, Beuzard Y, Chretien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M (2018) Gene therapy in patients with transfusion-dependent beta-thalassemia. N Engl J Med 378(16):1479\u20131493. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1705342","journal-title":"N Engl J Med"},{"issue":"25","key":"3695_CR4","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","volume":"123","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cawley SM, Li R, Wallner S, Alexander MJ, Mulivor AW, Gardenghi S, Rivella S, Grinberg AV, Pearsall RS, Kumar R (2014) Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia. Blood 123(25):3864\u20133872. \n                    https:\/\/doi.org\/10.1182\/blood-2013-06-511238","journal-title":"Blood"},{"issue":"12","key":"3695_CR5","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1182\/blood-2007-02-074849","volume":"111","author":"AE Ashley-Koch","year":"2008","unstructured":"Ashley-Koch AE, Elliott L, Kail ME, De Castro LM, Jonassaint J, Jackson TL, Price J, Ataga KI, Levesque MC, Weinberg JB, Orringer EP, Collins A, Vance JM, Telen MJ (2008) Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 111(12):5721\u20135726. \n                    https:\/\/doi.org\/10.1182\/blood-2007-02-074849","journal-title":"Blood"},{"issue":"2","key":"3695_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.hoc.2013.12.001","volume":"28","author":"L Breda","year":"2014","unstructured":"Breda L, Rivella S (2014) Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. Hematol Oncol Clin North Am 28(2):375\u2013386. \n                    https:\/\/doi.org\/10.1016\/j.hoc.2013.12.001","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"3695_CR7","doi-asserted-by":"publisher","first-page":"6974","DOI":"10.1002\/jcb.26906","volume":"119","author":"T Kajita","year":"2018","unstructured":"Kajita T, Ariyoshi W, Okinaga T, Mitsugi S, Tominaga K, Nishihara T (2018) Mechanisms involved in enhancement of osteoclast formation by activin-A. J Cell Biochem 119(8):6974\u20136985. \n                    https:\/\/doi.org\/10.1002\/jcb.26906","journal-title":"J Cell Biochem"},{"issue":"10","key":"3695_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1055\/s-0030-1249007","volume":"118","author":"N Rosenberg","year":"2010","unstructured":"Rosenberg N, Soudry M, Rosenberg O, Blumenfeld I, Blumenfeld Z (2010) The role of activin A in the human osteoblast cell cycle: a preliminary experimental in vitro study. Exp Clin Endocrinol Diabetes 118(10):708\u2013712. \n                    https:\/\/doi.org\/10.1055\/s-0030-1249007","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"10","key":"3695_CR9","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1074\/mcp.M112.024927","volume":"12","author":"RD Alves","year":"2013","unstructured":"Alves RD, Eijken M, Bezstarosti K, Demmers JA, van Leeuwen JP (2013) Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production. Mol Cell Proteomics 12(10):2890\u20132900. \n                    https:\/\/doi.org\/10.1074\/mcp.M112.024927","journal-title":"Mol Cell Proteomics"},{"issue":"1\u20132","key":"3695_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mce.2009.07.001","volume":"310","author":"KM Nicks","year":"2009","unstructured":"Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D (2009) Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, activin and inhibin. Mol Cell Endocrinol 310(1\u20132):11\u201320. \n                    https:\/\/doi.org\/10.1016\/j.mce.2009.07.001","journal-title":"Mol Cell Endocrinol"},{"key":"3695_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14789450.2016.1240622","volume":"13","author":"JB Arlet","year":"2016","unstructured":"Arlet JB, Guillem F, Lamarque M, Dussiot M, Maciel T, Moura I, Hermine O, Courtois G (2016) Protein-based therapeutic for anemia caused by dyserythropoiesis. Expert Rev Proteomics 13:1\u201310. \n                    https:\/\/doi.org\/10.1080\/14789450.2016.1240622","journal-title":"Expert Rev Proteomics"},{"issue":"6","key":"3695_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.12835","volume":"165","author":"KM Abdulkadyrov","year":"2014","unstructured":"Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E (2014) Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol 165(6):814\u2013823. \n                    https:\/\/doi.org\/10.1111\/bjh.12835","journal-title":"Br J Haematol"},{"issue":"2","key":"3695_CR13","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","volume":"5","author":"R Komrokji","year":"2018","unstructured":"Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF (2018) Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol 5(2):e63\u2013e72. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(18)30002-4","journal-title":"Lancet Haematol"},{"issue":"10","key":"3695_CR14","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A (2017) Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 18(10):1338\u20131347. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30615-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"3695_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1385\/JCD:3:2:107","volume":"3","author":"TV Nguyen","year":"2000","unstructured":"Nguyen TV, Pocock N, Eisman JA (2000) Interpretation of bone mineral density measurement and its change. J Clin Densitom 3(2):107\u2013119","journal-title":"J Clin Densitom"},{"issue":"10116","key":"3695_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","volume":"391","author":"AT Taher","year":"2018","unstructured":"Taher AT, Weatherall DJ, Cappellini MD (2018) Thalassaemia. Lancet 391(10116):155\u2013167. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)31822-6","journal-title":"Lancet"},{"issue":"9757","key":"3695_CR17","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","volume":"376","author":"DC Rees","year":"2010","unstructured":"Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376(9757):2018\u20132031. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)61029-X","journal-title":"Lancet"},{"issue":"1","key":"3695_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1385\/EP:17:1:19","volume":"17","author":"I Mylonas","year":"2006","unstructured":"Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Schulze S, Kainer F, Friese K (2006) Expression of inhibin\/activin subunits alpha (-alpha), betaA (-betaA), and betaB (-betaB) in placental tissue of normal, preeclamptic, and HELLP pregnancies. Endocr Pathol 17(1):19\u201333","journal-title":"Endocr Pathol"},{"issue":"11","key":"3695_CR19","first-page":"2599","volume":"69","author":"G Dhaliwal","year":"2004","unstructured":"Dhaliwal G, Cornett PA, Tierney LM Jr (2004) Hemolytic anemia. Am Fam Physician 69(11):2599\u20132606","journal-title":"Am Fam Physician"},{"issue":"1","key":"3695_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/0006-291X(88)90583-9","volume":"151","author":"M Murata","year":"1988","unstructured":"Murata M, Onomichi K, Eto Y, Shibai H, Muramatsu M (1988) Expression of erythroid differentiation factor (EDF) in Chinese hamster ovary cells. Biochem Biophys Res Commun 151(1):230\u2013235","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"3695_CR21","doi-asserted-by":"publisher","first-page":"9052","DOI":"10.1073\/pnas.85.23.9052","volume":"85","author":"HE Broxmeyer","year":"1988","unstructured":"Broxmeyer HE, Lu L, Cooper S, Schwall RH, Mason AJ, Nikolics K (1988) Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc Natl Acad Sci U S A 85(23):9052\u20139056","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3695_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1242\/dev.011767","volume":"135","author":"S Pearson","year":"2008","unstructured":"Pearson S, Sroczynska P, Lacaud G, Kouskoff V (2008) The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF. Development 135(8):1525\u20131535. \n                    https:\/\/doi.org\/10.1242\/dev.011767","journal-title":"Development"},{"issue":"6","key":"3695_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1634\/stemcells.20-6-493","volume":"20","author":"Y Shav-Tal","year":"2002","unstructured":"Shav-Tal Y, Zipori D (2002) The role of activin a in regulation of hemopoiesis. Stem Cells 20(6):493\u2013500. \n                    https:\/\/doi.org\/10.1634\/stemcells.20-6-493","journal-title":"Stem Cells"},{"issue":"3","key":"3695_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0301-472X(00)00675-5","volume":"29","author":"V Maguer-Satta","year":"2001","unstructured":"Maguer-Satta V, Bartholin L, Jeanpierre S, Gadoux M, Bertrand S, Martel S, Magaud JP, Rimokh R (2001) Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected]. Exp Hematol 29(3):301\u2013308","journal-title":"Exp Hematol"},{"issue":"4","key":"3695_CR25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1634\/stemcells.2005-0263","volume":"24","author":"T Utsugisawa","year":"2006","unstructured":"Utsugisawa T, Moody JL, Aspling M, Nilsson E, Carlsson L, Karlsson S (2006) A road map toward defining the role of Smad signaling in hematopoietic stem cells. Stem Cells 24(4):1128\u20131136. \n                    https:\/\/doi.org\/10.1634\/stemcells.2005-0263","journal-title":"Stem Cells"},{"issue":"5","key":"3695_CR26","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1073\/pnas.89.5.1553","volume":"89","author":"M Shiozaki","year":"1992","unstructured":"Shiozaki M, Sakai R, Tabuchi M, Nakamura T, Sugino K, Sugino H, Eto Y (1992) Evidence for the participation of endogenous activin A\/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci U S A 89(5):1553\u20131556","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3695_CR27","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/0006-291X(89)92723-X","volume":"165","author":"M Shiozaki","year":"1989","unstructured":"Shiozaki M, Sakai R, Tabuchi M, Eto Y, Kosaka M, Shibai H (1989) In vivo treatment with erythroid differentiation factor (EDF\/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice. Biochem Biophys Res Commun 165(3):1155\u20131161","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"3695_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0014-4827(02)00013-7","volume":"282","author":"V Maguer-Satta","year":"2003","unstructured":"Maguer-Satta V, Bartholin L, Jeanpierre S, Ffrench M, Martel S, Magaud JP, Rimokh R (2003) Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res 282(2):110\u2013120","journal-title":"Exp Cell Res"},{"issue":"4","key":"3695_CR29","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V73.4.952.952","volume":"73","author":"J Yu","year":"1989","unstructured":"Yu J, Shao L, Vaughan J, Vale W, Yu AL (1989) Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood 73(4):952\u2013960","journal-title":"Blood"},{"issue":"11","key":"3695_CR30","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood.V81.11.2891.2891","volume":"81","author":"T Mizuguchi","year":"1993","unstructured":"Mizuguchi T, Kosaka M, Saito S (1993) Activin A suppresses proliferation of interleukin-3-responsive granulocyte-macrophage colony-forming progenitors and stimulates proliferation and differentiation of interleukin-3-responsive erythroid burst-forming progenitors in the peripheral blood. Blood 81(11):2891\u20132897","journal-title":"Blood"},{"issue":"11","key":"3695_CR31","first-page":"1090","volume":"19","author":"K Nakao","year":"1991","unstructured":"Nakao K, Kosaka M, Saito S (1991) Effects of erythroid differentiation factor (EDF) on proliferation and differentiation of human hematopoietic progenitors. Exp Hematol 19(11):1090\u20131095","journal-title":"Exp Hematol"},{"issue":"3","key":"3695_CR32","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/0006-291X(87)91528-2","volume":"142","author":"Y Eto","year":"1987","unstructured":"Eto Y, Tsuji T, Takezawa M, Takano S, Yokogawa Y, Shibai H (1987) Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1. Biochem Biophys Res Commun 142(3):1095\u20131103","journal-title":"Biochem Biophys Res Commun"},{"issue":"6150","key":"3695_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/330765a0","volume":"330","author":"J Yu","year":"1987","unstructured":"Yu J, Shao LE, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W (1987) Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 330(6150):765\u2013767. \n                    https:\/\/doi.org\/10.1038\/330765a0","journal-title":"Nature"},{"issue":"3","key":"3695_CR34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1182\/blood.V79.3.765.765","volume":"79","author":"NL Frigon Jr","year":"1992","unstructured":"Frigon NL Jr, Shao L, Young AL, Maderazo L, Yu J (1992) Regulation of globin gene expression in human K562 cells by recombinant activin A. Blood 79(3):765\u2013772","journal-title":"Blood"},{"issue":"3","key":"3695_CR35","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1210\/endo-125-3-1420","volume":"125","author":"R Schwall","year":"1989","unstructured":"Schwall R, Schmelzer CH, Matsuyama E, Mason AJ (1989) Multiple actions of recombinant activin-A in vivo. Endocrinology 125(3):1420\u20131423. \n                    https:\/\/doi.org\/10.1210\/endo-125-3-1420","journal-title":"Endocrinology"},{"issue":"6","key":"3695_CR36","first-page":"447","volume":"54","author":"HE Broxmeyer","year":"1991","unstructured":"Broxmeyer HE, Hangoc G, Zucali JR, Mason A, Schwall R, Carow C, Cooper S (1991) Effects in vivo of purified recombinant human activin and erythropoietin in mice. Int J Hematol 54(6):447\u2013454","journal-title":"Int J Hematol"},{"key":"3695_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.04569.x","volume":"1176","author":"SS Soderberg","year":"2009","unstructured":"Soderberg SS, Karlsson G, Karlsson S (2009) Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Ann N Y Acad Sci 1176:55\u201369. \n                    https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04569.x","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"3695_CR38","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00198-012-2198-0","volume":"24","author":"AD Anastasilakis","year":"2013","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Savvides M, Papatheodorou A, Terpos E (2013) Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. Osteoporos Int 24(7):2127\u20132132. \n                    https:\/\/doi.org\/10.1007\/s00198-012-2198-0","journal-title":"Osteoporos Int"},{"issue":"10","key":"3695_CR39","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/annonc\/mds068","volume":"23","author":"E Terpos","year":"2012","unstructured":"Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA (2012) Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 23(10):2681\u20132686. \n                    https:\/\/doi.org\/10.1093\/annonc\/mds068","journal-title":"Ann Oncol"},{"issue":"11","key":"3695_CR40","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"S Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 107(11):5124\u20135129. \n                    https:\/\/doi.org\/10.1073\/pnas.0911929107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3695_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","volume":"23","author":"G Leto","year":"2006","unstructured":"Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G (2006) Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23(2):117\u2013122. \n                    https:\/\/doi.org\/10.1007\/s10585-006-9010-5","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"3695_CR42","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/asheducation-2017.1.272","volume":"2017","author":"A Piga","year":"2017","unstructured":"Piga A (2017) Impact of bone disease and pain in thalassemia. Hematology Am Soc Hematol Educ Program 2017(1):272\u2013277. \n                    https:\/\/doi.org\/10.1182\/asheducation-2017.1.272","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"3695_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.0.CO;2-T","volume":"75","author":"T Ikenoue","year":"1999","unstructured":"Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y (1999) Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 75(2):206\u2013214","journal-title":"J Cell Biochem"},{"issue":"3","key":"3695_CR44","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.bone.2011.11.016","volume":"50","author":"GG Loots","year":"2012","unstructured":"Loots GG, Keller H, Leupin O, Murugesh D, Collette NM, Genetos DC (2012) TGF-beta regulates sclerostin expression via the ECR5 enhancer. Bone 50(3):663\u2013669. \n                    https:\/\/doi.org\/10.1016\/j.bone.2011.11.016","journal-title":"Bone"},{"issue":"12","key":"3695_CR45","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1055\/s-0032-1312618","volume":"44","author":"E Voskaridou","year":"2012","unstructured":"Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909\u2013913. \n                    https:\/\/doi.org\/10.1055\/s-0032-1312618","journal-title":"Horm Metab Res"},{"issue":"4","key":"3695_CR46","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1359\/jbmr.081208","volume":"24","author":"J Ruckle","year":"2009","unstructured":"Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24(4):744\u2013752. \n                    https:\/\/doi.org\/10.1359\/jbmr.081208","journal-title":"J Bone Miner Res"},{"issue":"4","key":"3695_CR47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nm.3468","volume":"20","author":"M Dussiot","year":"2014","unstructured":"Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, Grapton D, Paubelle E, Payen E, Beuzard Y, Leboulch P, Ribeil JA, Arlet JB, Cote F, Courtois G, Ginzburg YZ, Daniel TO, Chopra R, Sung V, Hermine O, Moura IC (2014) An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nat Med 20(4):398\u2013407. \n                    https:\/\/doi.org\/10.1038\/nm.3468","journal-title":"Nat Med"},{"issue":"6","key":"3695_CR48","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/bjh.12838","volume":"165","author":"S Carrancio","year":"2014","unstructured":"Carrancio S, Markovics J, Wong P, Leisten J, Castiglioni P, Groza MC, Raymon HK, Heise C, Daniel T, Chopra R, Sung V (2014) An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol 165(6):870\u2013882. \n                    https:\/\/doi.org\/10.1111\/bjh.12838","journal-title":"Br J Haematol"},{"issue":"2","key":"3695_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","volume":"41","author":"C Iancu-Rubin","year":"2013","unstructured":"Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R (2013) Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 41(2):155\u2013166 e117. \n                    https:\/\/doi.org\/10.1016\/j.exphem.2012.12.002","journal-title":"Exp Hematol"},{"key":"3695_CR50","unstructured":"Flotta S, Delbini P, Graziadei G, Marcon A, Sung V, Cappellini MD (2015) Erythropoietic response to a ligand trap of activin receptor II in cultures from \u03b2-thalassemia patients. EHA Learning Center. Flotta S. 102769"},{"issue":"1","key":"3695_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ajh.23856","volume":"90","author":"JM Langdon","year":"2015","unstructured":"Langdon JM, Barkataki S, Berger AE, Cheadle C, Xue QL, Sung V, Roy CN (2015) RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol 90(1):8\u201314. \n                    https:\/\/doi.org\/10.1002\/ajh.23856","journal-title":"Am J Hematol"},{"key":"3695_CR52","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood.V122.21.3441.3441","volume":"122","author":"M Malek","year":"2013","unstructured":"Malek M, Heise C, Chopra R, Daniel TO, Sung V (2013) Sotatercept, an activin receptor-2a ligand trap, modulates hepcidin levels in primary human hepatocytes. Blood 122:3441","journal-title":"Blood"},{"key":"3695_CR53","unstructured":"Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Taher AT, Laadem A, Galact\u00e9ros F, Miteva D, Sung V, Chopra R, Arlet J-B, Ribeil J-A, Zou J, Chen N, Attie KM, Garbowski M, Graziadei G, Balocco M, Hermine O (2015) Interim results from a phase 2a, open-label, dose-finding study of sotatercept (ACE-011) in adult patients (pts) with beta-thalassemia. EHA Learning Center. Domenica Cappellini M. 103081"},{"key":"3695_CR54","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood.V128.22.2439.2439","volume":"128","author":"P Oikonomidou","year":"2016","unstructured":"Oikonomidou P, La P, Gupta R, Presti V, Casu C, Breda L, Watson D, Suragani R, Kumar R, Rivella S (2016) Genetic investigation of the role of GDF11 in the treatment of \u03b2-thalassemia and MDS. Blood 128:2439","journal-title":"Blood"},{"issue":"4","key":"3695_CR55","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R (2014) Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20(4):408\u2013414. \n                    https:\/\/doi.org\/10.1038\/nm.3512","journal-title":"Nat Med"},{"key":"3695_CR56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.V126.23.751.751","volume":"126","author":"PA Martinez","year":"2015","unstructured":"Martinez PA, Suragani RN, Bhasin M, Li R, Pearsall RS, Kumar R (2015) Rap-536 (murine ACE-536\/luspatercept) inhibits Smad2\/3 signaling and promotes erythroid differentiation by restoring GATA-1 function in murine b-thalassemia. Blood 126:751","journal-title":"Blood"},{"key":"3695_CR57","unstructured":"Piga A, Tartaglione I, Gamberini MR, Voskaridou E, Melpignano A, Ricchi P, Caruso V, Pietrangelo A, Reynolds J, Barron C, Zhang X, Laadem A, Linde PG, Sherman ML (2018) Improvements in hemoglobin, quality of life, and six-minute-walk distance in adults with b-thalassemia treated with luspatercept: long-term phase 2 study. EHA Learning Center. Piga A. 214458"},{"key":"3695_CR58","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"N Chen","year":"2016","unstructured":"Chen N, Laadem A, Wilson DM, Zhang X, Sherman ML, Ritland S, Attie KM (2016) Pharmacokinetics and exposure-response of luspatercept in patients with beta-thalassemia: preliminary results from phase 2 studies. Blood 128:2463","journal-title":"Blood"},{"key":"3695_CR59","unstructured":"Piga A, Perrotta S, Melpignano A, Borgna-Pignatti C, Gamberini MR, Voskaridou E, Caruso V, Ricchi P, Pietrangelo A, Zhang X, Wilson D, Bellevue A, Laadem A, Sherman M, Attie K (2016) Luspatercept decreases transfusion burden and liver iron concentration in regularly transfused adults with beta-thalassemia. EHA Learning Center. Piga A. 135330"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03695-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03695-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03695-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T23:11:12Z","timestamp":1588115472000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03695-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3695"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03695-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}